Biophan Issued Two New U.S. Patents Enabling Advances in MRI Compatibility and Safety for Medical Devices.

ROCHESTER, N.Y. -- Additional Patents Strengthen Company's Intellectual Property Protection in Nanotechnology and Photonics

Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, has announced the issuance of two new patents by the U.S. Patent and Trademark Office that further extend the Company's competitive edge in the marketplace for the rapidly emerging field of magnetic resonance imaging (MRI) safety and image compatibility for surgical instruments and implanted devices.

The new patents, involving nanomagnetic coatings and advanced fiber-optics, adds important capability to Biophan's overall offerings of proprietary solutions that make medical devices safe and image compatible within the MRI environment. They further substantiate Biophan's competitive edge and leadership position within the marketplace for improving more than $12 billion of medical devices that do not have MRI safety and image compatibility.

"These patent issuances continue Biophan's growth and business strategy to develop a base of protected intellectual property in key medical areas," said Michael Weiner, CEO of Biophan. "As we extend our patents and claims covering important medical innovations--such as the ability to make MRI-image-compatible and MRI-safe devices--we strengthen the certainty that manufacturers of medical equipment will license our technology and avoid the risk of infringement and litigation. The broad coverage that Biophan has been diligent in obtaining also makes it attractive to our customers to consider an exclusive license for certain fields of strategic interest to them, because they realize that our broad patent position will allow them to defend their exclusive position in market segments important to them."

One of the new patents covers new methods to produce a variety of nanomagnetic coatings to shield medical equipment within an MRI environment. It includes a broad claim regarding how these coatings can be used in a variety of applications, including the reduction of heating in medical devices under MRI; to selectively generate heat for cancer treatments or to control drug release; to reduce image artifacts under MRI; or to enable unimpeded MRI visualization of devices that have been traditionally difficult to see effectively under MRI.

The other newly issued patent extends the Company's protection for next-generation MRI-safe techniques utilizing fiber-optics to power biomedical sensors and therapeutic devices.

Fiber-optic cables are thin and flexible enough to fit into blood vessels and capillaries, and can carry extraordinarily large amounts of data. However, powering a remote biosensor at the end of the fiber optic cable has traditionally been a problem. The new Biophan patent teaches how a variety of sensors, probes, and medical therapies can be remotely powered and can communicate over a fiber-optic cable by powering the remote probe with short pulses of light. The light energy is converted to electrical energy to power the probes and to send data back to a device where they can be analyzed. This technology can be applied to devices used outside the body or part of an implantable device. The patent is one of more than twenty Biophan patents, issued or pending, that teach the use of photonics and fiber-optics in biosensing and disease treatment.

We are very pleased to be receiving broad patents for photonic applications that we believe can serve an important role in the future of medical devices, both interventional and implanted. We believe that a range of future implantable and surgical medical devices will use photonic solutions, and we are pleased to have a large and growing patent portfolio covering this emerging capability.

In related news, Biophan announced that it had closed a term sheet with a major biomedical device company, but due to confidentiality agreements governing the transaction, will not be announcing details until the transaction closes. "We are very pleased with the transaction and its forward progress," said Mr. Weiner. "The agreement will be more than adequate to provide the capital needed to enable our listing on a major stock exchange. We are in the process of preparing our listing application."

About Biophan Technologies

Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers and interventional surgical devices such as catheters, guidewires, stents, and other implants to allow them to be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan technologies include advances in nanotechnology and thin-film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors now hold a total of 106 U.S. patents, licenses, or applications. This total includes 30 issued U.S. patents, 8 recently-allowed applications that will issue as patents in the near future, and 68 pending applications at various stages of examination at the U.S. Patent and Trademark Office. The patents cover areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE: BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com. To view the Company's Investor Fact Sheet, or ongoing installments of "Biophan 101" informational videos about aspects of the Company's next-generation biomedical solutions, visit http://www.trilogy-capital.com/tcp/html/biophan.htm.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.